Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing
Objective Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 2007-07, Vol.151 (1), p.34-42.e1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42.e1 |
|---|---|
| container_issue | 1 |
| container_start_page | 34 |
| container_title | The Journal of pediatrics |
| container_volume | 151 |
| creator | Simoes, Eric A.F., MB, BS, DCH, MD Groothuis, Jessie R., MD Carbonell-Estrany, Xavier, MD, PhD Rieger, Christian H.L., MD Mitchell, Ian, MA, MB, ChB Fredrick, Linda M., MS Kimpen, Jan L.L., MD, PhD |
| description | Objective Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants without chronic lung disease. We hypothesized that palivizumab, by ameliorating or preventing early RSV LRTI in preterm infants, might decrease later recurrent wheezing. Study design A cohort of preterm infants who had received palivizumab and were not hospitalized for RSV (n = 191) or who never received palivizumab (n = 230; 76 who were hospitalized for RSV and 154 who were not), were prospectively followed for 24 months beginning at a mean age of 19 months. The subjects were assessed for recurrent wheezing by caretaker or physician report. Results The incidences of recurrent wheezing and physician-diagnosed recurrent wheezing were significantly lower in the 191 palivizumab-treated subjects (13% and 8%, respectively) compared with all 230 untreated subjects (26%, P = .001 and 16%, P = .011, respectively) and with the 154 patients in the subgroup not hospitalized for RSV LRTI (23%, P = .022 and 16%, P = .027, respectively). The effect of palivizumab treatment remained significant after adjustment for potential confounding variables. Conclusions Our study suggests that preventing RSV LRTI with palivizumab may reduce subsequent recurrent wheezing in premature infants. |
| doi_str_mv | 10.1016/j.jpeds.2007.02.032 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70651475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347607001618</els_id><sourcerecordid>70651475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-3833f4776e20c7a57a94b0f7c7c6e9ed50460aff804900961bc67b646ff7b1cb3</originalsourceid><addsrcrecordid>eNqFkVFr1TAYhoMo7mz6CwTpjV7Z7kubJu2FggzdhIFjR91lSNMvLrUnrUk71v16U8-BgTdeJZDn_fLyfIS8opBRoPy0y7oR25DlACKDPIMif0I2FGqR8qoonpINQJ6nBRP8iByH0AFAzQCekyMqyorTqtqQmyvV2zv7MO9Uk1z5YbxdenVvw7vkGsNovZoGvyTbxellsqpPflg_x0fl2mQ7NwF_z-imyOrZ-_V2c4v4YN3PF-SZUX3Al4fzhHz__Onb2UV6-fX8y9nHy1Qzlk9pEYsaJgTHHLRQpVA1a8AILTTHGtsSGAdlTAWsju05bTQXDWfcGNFQ3RQn5O1-7uiH2CVMcmeDxr5XDoc5SAG8pEyUESz2oPZDCB6NHL3dKb9ICnL1KTv516dcfUrIZfQZU68P4-dmh-1j5iAwAm8OgApa9cYrp2145GpaRwoi937PYZRxZ9HLoC06ja31qCfZDvY_RT78k9e9dTZ--QsXDN0wexc9SypDDMjtuvp18yAgjqRV8QfK0aow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70651475</pqid></control><display><type>article</type><title>Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Simoes, Eric A.F., MB, BS, DCH, MD ; Groothuis, Jessie R., MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda M., MS ; Kimpen, Jan L.L., MD, PhD</creator><creatorcontrib>Simoes, Eric A.F., MB, BS, DCH, MD ; Groothuis, Jessie R., MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda M., MS ; Kimpen, Jan L.L., MD, PhD ; Palivizumab Long-Term Respiratory Outcomes Study Group</creatorcontrib><description>Objective Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants without chronic lung disease. We hypothesized that palivizumab, by ameliorating or preventing early RSV LRTI in preterm infants, might decrease later recurrent wheezing. Study design A cohort of preterm infants who had received palivizumab and were not hospitalized for RSV (n = 191) or who never received palivizumab (n = 230; 76 who were hospitalized for RSV and 154 who were not), were prospectively followed for 24 months beginning at a mean age of 19 months. The subjects were assessed for recurrent wheezing by caretaker or physician report. Results The incidences of recurrent wheezing and physician-diagnosed recurrent wheezing were significantly lower in the 191 palivizumab-treated subjects (13% and 8%, respectively) compared with all 230 untreated subjects (26%, P = .001 and 16%, P = .011, respectively) and with the 154 patients in the subgroup not hospitalized for RSV LRTI (23%, P = .022 and 16%, P = .027, respectively). The effect of palivizumab treatment remained significant after adjustment for potential confounding variables. Conclusions Our study suggests that preventing RSV LRTI with palivizumab may reduce subsequent recurrent wheezing in premature infants.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/j.jpeds.2007.02.032</identifier><identifier>PMID: 17586188</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Antiviral Agents - administration & dosage ; Biological and medical sciences ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Female ; Follow-Up Studies ; General aspects ; Hospitalization - statistics & numerical data ; Human viral diseases ; Humans ; Infant, Newborn ; Infant, Premature ; Infectious diseases ; Logistic Models ; Male ; Medical sciences ; Multivariate Analysis ; Palivizumab ; Pediatrics ; Prevention and actions ; Probability ; Prospective Studies ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Reference Values ; Respiratory Sounds - diagnosis ; Respiratory Sounds - drug effects ; Respiratory Syncytial Virus Infections - drug therapy ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Viruses - drug effects ; Risk Assessment ; Secondary Prevention ; Treatment Outcome ; Viral diseases ; Viral diseases of the respiratory system and ent viral diseases</subject><ispartof>The Journal of pediatrics, 2007-07, Vol.151 (1), p.34-42.e1</ispartof><rights>Mosby, Inc.</rights><rights>2007 Mosby, Inc.</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-3833f4776e20c7a57a94b0f7c7c6e9ed50460aff804900961bc67b646ff7b1cb3</citedby><cites>FETCH-LOGICAL-c442t-3833f4776e20c7a57a94b0f7c7c6e9ed50460aff804900961bc67b646ff7b1cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022347607001618$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19198830$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17586188$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Simoes, Eric A.F., MB, BS, DCH, MD</creatorcontrib><creatorcontrib>Groothuis, Jessie R., MD</creatorcontrib><creatorcontrib>Carbonell-Estrany, Xavier, MD, PhD</creatorcontrib><creatorcontrib>Rieger, Christian H.L., MD</creatorcontrib><creatorcontrib>Mitchell, Ian, MA, MB, ChB</creatorcontrib><creatorcontrib>Fredrick, Linda M., MS</creatorcontrib><creatorcontrib>Kimpen, Jan L.L., MD, PhD</creatorcontrib><creatorcontrib>Palivizumab Long-Term Respiratory Outcomes Study Group</creatorcontrib><title>Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>Objective Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants without chronic lung disease. We hypothesized that palivizumab, by ameliorating or preventing early RSV LRTI in preterm infants, might decrease later recurrent wheezing. Study design A cohort of preterm infants who had received palivizumab and were not hospitalized for RSV (n = 191) or who never received palivizumab (n = 230; 76 who were hospitalized for RSV and 154 who were not), were prospectively followed for 24 months beginning at a mean age of 19 months. The subjects were assessed for recurrent wheezing by caretaker or physician report. Results The incidences of recurrent wheezing and physician-diagnosed recurrent wheezing were significantly lower in the 191 palivizumab-treated subjects (13% and 8%, respectively) compared with all 230 untreated subjects (26%, P = .001 and 16%, P = .011, respectively) and with the 154 patients in the subgroup not hospitalized for RSV LRTI (23%, P = .022 and 16%, P = .027, respectively). The effect of palivizumab treatment remained significant after adjustment for potential confounding variables. Conclusions Our study suggests that preventing RSV LRTI with palivizumab may reduce subsequent recurrent wheezing in premature infants.</description><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>General aspects</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Infant, Premature</subject><subject>Infectious diseases</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Multivariate Analysis</subject><subject>Palivizumab</subject><subject>Pediatrics</subject><subject>Prevention and actions</subject><subject>Probability</subject><subject>Prospective Studies</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Reference Values</subject><subject>Respiratory Sounds - diagnosis</subject><subject>Respiratory Sounds - drug effects</subject><subject>Respiratory Syncytial Virus Infections - drug therapy</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Syncytial Viruses - drug effects</subject><subject>Risk Assessment</subject><subject>Secondary Prevention</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral diseases of the respiratory system and ent viral diseases</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVFr1TAYhoMo7mz6CwTpjV7Z7kubJu2FggzdhIFjR91lSNMvLrUnrUk71v16U8-BgTdeJZDn_fLyfIS8opBRoPy0y7oR25DlACKDPIMif0I2FGqR8qoonpINQJ6nBRP8iByH0AFAzQCekyMqyorTqtqQmyvV2zv7MO9Uk1z5YbxdenVvw7vkGsNovZoGvyTbxellsqpPflg_x0fl2mQ7NwF_z-imyOrZ-_V2c4v4YN3PF-SZUX3Al4fzhHz__Onb2UV6-fX8y9nHy1Qzlk9pEYsaJgTHHLRQpVA1a8AILTTHGtsSGAdlTAWsju05bTQXDWfcGNFQ3RQn5O1-7uiH2CVMcmeDxr5XDoc5SAG8pEyUESz2oPZDCB6NHL3dKb9ICnL1KTv516dcfUrIZfQZU68P4-dmh-1j5iAwAm8OgApa9cYrp2145GpaRwoi937PYZRxZ9HLoC06ja31qCfZDvY_RT78k9e9dTZ--QsXDN0wexc9SypDDMjtuvp18yAgjqRV8QfK0aow</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>Simoes, Eric A.F., MB, BS, DCH, MD</creator><creator>Groothuis, Jessie R., MD</creator><creator>Carbonell-Estrany, Xavier, MD, PhD</creator><creator>Rieger, Christian H.L., MD</creator><creator>Mitchell, Ian, MA, MB, ChB</creator><creator>Fredrick, Linda M., MS</creator><creator>Kimpen, Jan L.L., MD, PhD</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070701</creationdate><title>Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing</title><author>Simoes, Eric A.F., MB, BS, DCH, MD ; Groothuis, Jessie R., MD ; Carbonell-Estrany, Xavier, MD, PhD ; Rieger, Christian H.L., MD ; Mitchell, Ian, MA, MB, ChB ; Fredrick, Linda M., MS ; Kimpen, Jan L.L., MD, PhD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-3833f4776e20c7a57a94b0f7c7c6e9ed50460aff804900961bc67b646ff7b1cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>General aspects</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Infant, Premature</topic><topic>Infectious diseases</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Multivariate Analysis</topic><topic>Palivizumab</topic><topic>Pediatrics</topic><topic>Prevention and actions</topic><topic>Probability</topic><topic>Prospective Studies</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Reference Values</topic><topic>Respiratory Sounds - diagnosis</topic><topic>Respiratory Sounds - drug effects</topic><topic>Respiratory Syncytial Virus Infections - drug therapy</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Syncytial Viruses - drug effects</topic><topic>Risk Assessment</topic><topic>Secondary Prevention</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral diseases of the respiratory system and ent viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simoes, Eric A.F., MB, BS, DCH, MD</creatorcontrib><creatorcontrib>Groothuis, Jessie R., MD</creatorcontrib><creatorcontrib>Carbonell-Estrany, Xavier, MD, PhD</creatorcontrib><creatorcontrib>Rieger, Christian H.L., MD</creatorcontrib><creatorcontrib>Mitchell, Ian, MA, MB, ChB</creatorcontrib><creatorcontrib>Fredrick, Linda M., MS</creatorcontrib><creatorcontrib>Kimpen, Jan L.L., MD, PhD</creatorcontrib><creatorcontrib>Palivizumab Long-Term Respiratory Outcomes Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simoes, Eric A.F., MB, BS, DCH, MD</au><au>Groothuis, Jessie R., MD</au><au>Carbonell-Estrany, Xavier, MD, PhD</au><au>Rieger, Christian H.L., MD</au><au>Mitchell, Ian, MA, MB, ChB</au><au>Fredrick, Linda M., MS</au><au>Kimpen, Jan L.L., MD, PhD</au><aucorp>Palivizumab Long-Term Respiratory Outcomes Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>151</volume><issue>1</issue><spage>34</spage><epage>42.e1</epage><pages>34-42.e1</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>Objective Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants without chronic lung disease. We hypothesized that palivizumab, by ameliorating or preventing early RSV LRTI in preterm infants, might decrease later recurrent wheezing. Study design A cohort of preterm infants who had received palivizumab and were not hospitalized for RSV (n = 191) or who never received palivizumab (n = 230; 76 who were hospitalized for RSV and 154 who were not), were prospectively followed for 24 months beginning at a mean age of 19 months. The subjects were assessed for recurrent wheezing by caretaker or physician report. Results The incidences of recurrent wheezing and physician-diagnosed recurrent wheezing were significantly lower in the 191 palivizumab-treated subjects (13% and 8%, respectively) compared with all 230 untreated subjects (26%, P = .001 and 16%, P = .011, respectively) and with the 154 patients in the subgroup not hospitalized for RSV LRTI (23%, P = .022 and 16%, P = .027, respectively). The effect of palivizumab treatment remained significant after adjustment for potential confounding variables. Conclusions Our study suggests that preventing RSV LRTI with palivizumab may reduce subsequent recurrent wheezing in premature infants.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>17586188</pmid><doi>10.1016/j.jpeds.2007.02.032</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 2007-07, Vol.151 (1), p.34-42.e1 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70651475 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antiviral Agents - administration & dosage Biological and medical sciences Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies General aspects Hospitalization - statistics & numerical data Human viral diseases Humans Infant, Newborn Infant, Premature Infectious diseases Logistic Models Male Medical sciences Multivariate Analysis Palivizumab Pediatrics Prevention and actions Probability Prospective Studies Public health. Hygiene Public health. Hygiene-occupational medicine Reference Values Respiratory Sounds - diagnosis Respiratory Sounds - drug effects Respiratory Syncytial Virus Infections - drug therapy Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Viruses - drug effects Risk Assessment Secondary Prevention Treatment Outcome Viral diseases Viral diseases of the respiratory system and ent viral diseases |
| title | Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A50%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Palivizumab%20Prophylaxis,%20Respiratory%20Syncytial%20Virus,%20and%20Subsequent%20Recurrent%20Wheezing&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Simoes,%20Eric%20A.F.,%20MB,%20BS,%20DCH,%20MD&rft.aucorp=Palivizumab%20Long-Term%20Respiratory%20Outcomes%20Study%20Group&rft.date=2007-07-01&rft.volume=151&rft.issue=1&rft.spage=34&rft.epage=42.e1&rft.pages=34-42.e1&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/j.jpeds.2007.02.032&rft_dat=%3Cproquest_cross%3E70651475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70651475&rft_id=info:pmid/17586188&rft_els_id=S0022347607001618&rfr_iscdi=true |